Plain-English translation of NCT05591027 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 safety study of Centella asiatica water extract (CAP) for older adults with mild cognitive impairment or mild Alzheimer's disease. Researchers want to see if this plant-based treatment is safe to take and whether it affects markers in the brain related to memory, stress damage to cells, and energy production. You'll take the medication or a look-alike placebo daily for six weeks while researchers monitor your health and brain function.
Memory loss and Alzheimer's disease damage brain cells and disrupt the brain's energy systems. This medication has shown promise in laboratory studies for protecting brain cells and reducing cellular stress, but it has never been tested in humans with these conditions—so researchers need to first confirm it's safe.
You likely qualify if…
You likely don't qualify if…
You will visit the study site at least twice—once to start and once after six weeks. At each visit, you'll have blood tests, brain imaging scans (MRI), and memory or thinking tests. Between visits, you'll mix a sachet of the medication (or placebo) into water and drink it once daily for six weeks. You'll need to stop taking any herbal supplements one week before the study and keep a caregiver involved throughout.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Oregon Health and Science University
Collaborators
Alzheimer's Association
Enrollment target
~48 participants
Started
December 2022
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
60 Years – 85 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amala Soumyanath, PhD
Oregon Health and Science University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.